Sign In
Buy CLSD
$0.410
+0 (+0%)
At Close: Mar 13, 2026
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
07:05am, Tuesday, 02'nd Apr 2024
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
07:05am, Monday, 18'th Mar 2024
Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development Industry Veteran with Extensive Experience in Retinal
Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript
12:47am, Wednesday, 13'th Mar 2024
Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 12'th Mar 2024
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector ® - - Strengthened C
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
01:37pm, Sunday, 25'th Feb 2024
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
08:00am, Wednesday, 07'th Feb 2024
ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therap
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
07:05am, Thursday, 14'th Dec 2023
- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside's SCS Microinjector ® - - Randomization Completed in ODYSSEY Phase 2b Clinical Trial - - Topline Dat
Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript
07:18pm, Monday, 13'th Nov 2023
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Charlie Deignan - CFO Conference Call
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
04:05pm, Monday, 13'th Nov 2023
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside's Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor -
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
07:05am, Wednesday, 08'th Nov 2023
ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Robust Safety Profile and Encouraging Efficacy Data Utilizing SCS Microinjector® Featured in Multiple Data Presentations Robust Safety Profile and Encouraging Efficacy Data Utilizing SCS Microinjecto
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
07:05am, Thursday, 02'nd Nov 2023
Clearside Biomedical announced that multiple oral & poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Mtg.
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
07:05am, Wednesday, 01'st Nov 2023
- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- C
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023
07:05am, Tuesday, 31'st Oct 2023
ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
